Scott Otallah1, Brenda Banwell2,3. 1. Pediatric Multiple Sclerosis and Demyelinating Disorders Clinic, Division of Pediatric Neurology, Department of Neurology, Wake Forest University/Brenner Children's Hospital, Medical Center Boulevard, JT9, Winston Salem, NC, 27157, USA. sotallah@wakehealth.edu. 2. Children's Hospital of Philadelphia, Philadelphia, PA, USA. 3. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
PURPOSE OF REVIEW: Diagnostic criteria for pediatric-onset multiple sclerosis (POMS) and related demyelinating disorders have been updated, neuroimaging studies have revealed new insights, biological assays identify patients with specific antibodies that influence both diagnosis and treatment, clinical trials are informing on treatment efficacy and safety, and longitudinal studies of neurological, cognitive and quality of life outcomes are informing on the impact of these diseases. We provide updates to assist providers caring for these children. RECENT FINDINGS: The recent 2017 McDonald Criteria for MS provide a simplified means to confirm diagnosis at onset and over time, and have been shown to be equally applicable for POMS. MRI analyses demonstrate that brain volume is reduced at onset, and that both volumetric and tissue integrity measures decline over time, indicating that POMS shares the degenerative aspects that also characterize adult-onset disease. The presence of myelin oligodendrocyte glycoprotein (MOG) antibodies at onset is detected in more than 50% of children with acute disseminated encephalomyelitis. When persistent over time, they are associated with relapsing disease. The first randomized clinical trials of disease supports superiority of fingolimod over subcutaneous interferon beta 1a, and demonstrated a favorable safety profile. Finally, while Expanded Disability Status Scale (EDSS) scores remain low in the first 10 years post-onset, POMS is associated with high rates of patient-reported fatigue and reduced engagement in exercise and carries a risk for cognitive impairment. The past 15 years have borne witness to a marked expansion in recognition and research in POMS. There are now more specific diagnostic criteria, antibodies to CNS proteins appear to define diagnostically distinct disorders, clinical trials have successfully launched and one has completed, and we are gaining increasing appreciation of the impact of MS and related disorders on the lived experience of children and adolescents.
PURPOSE OF REVIEW: Diagnostic criteria for pediatric-onset multiple sclerosis (POMS) and related demyelinating disorders have been updated, neuroimaging studies have revealed new insights, biological assays identify patients with specific antibodies that influence both diagnosis and treatment, clinical trials are informing on treatment efficacy and safety, and longitudinal studies of neurological, cognitive and quality of life outcomes are informing on the impact of these diseases. We provide updates to assist providers caring for these children. RECENT FINDINGS: The recent 2017 McDonald Criteria for MS provide a simplified means to confirm diagnosis at onset and over time, and have been shown to be equally applicable for POMS. MRI analyses demonstrate that brain volume is reduced at onset, and that both volumetric and tissue integrity measures decline over time, indicating that POMS shares the degenerative aspects that also characterize adult-onset disease. The presence of myelin oligodendrocyte glycoprotein (MOG) antibodies at onset is detected in more than 50% of children with acute disseminated encephalomyelitis. When persistent over time, they are associated with relapsing disease. The first randomized clinical trials of disease supports superiority of fingolimod over subcutaneous interferon beta 1a, and demonstrated a favorable safety profile. Finally, while Expanded Disability Status Scale (EDSS) scores remain low in the first 10 years post-onset, POMS is associated with high rates of patient-reported fatigue and reduced engagement in exercise and carries a risk for cognitive impairment. The past 15 years have borne witness to a marked expansion in recognition and research in POMS. There are now more specific diagnostic criteria, antibodies to CNS proteins appear to define diagnostically distinct disorders, clinical trials have successfully launched and one has completed, and we are gaining increasing appreciation of the impact of MS and related disorders on the lived experience of children and adolescents.
Authors: Ajit Singh Dhaunchak; Christopher Becker; Howard Schulman; Omar De Faria; Sathyanath Rajasekharan; Brenda Banwell; David R Colman; Amit Bar-Or Journal: Ann Neurol Date: 2012-04-04 Impact factor: 10.422
Authors: E Daniëlle van Pelt; Julia Y Mescheriakova; Nalia Makhani; Immy A Ketelslegers; Rinze F Neuteboom; Suman Kundu; Linda Broer; Cecile Janssens; Coriene E Catsman-Berrevoets; Cornelia M van Duijn; Brenda Banwell; Amit Bar-Or; Rogier Q Hintzen Journal: Neurology Date: 2013-11-06 Impact factor: 9.910
Authors: Milena A Gianfrancesco; Pernilla Stridh; Xiaorong Shao; Brooke Rhead; Jennifer S Graves; Tanuja Chitnis; Amy Waldman; Timothy Lotze; Teri Schreiner; Anita Belman; Benjamin Greenberg; Bianca Weinstock-Guttman; Gregory Aaen; Jan M Tillema; Janace Hart; Stacy Caillier; Jayne Ness; Yolanda Harris; Jennifer Rubin; Meghan Candee; Lauren Krupp; Mark Gorman; Leslie Benson; Moses Rodriguez; Soe Mar; Ilana Kahn; John Rose; Shelly Roalstad; T Charles Casper; Ling Shen; Hong Quach; Diana Quach; Jan Hillert; Anna Hedstrom; Tomas Olsson; Ingrid Kockum; Lars Alfredsson; Catherine Schaefer; Lisa F Barcellos; Emmanuelle Waubant Journal: Mult Scler Date: 2017-10-05 Impact factor: 6.312
Authors: Helen Tremlett; Douglas W Fadrosh; Ali A Faruqi; Janace Hart; Shelly Roalstad; Jennifer Graves; Susan Lynch; Emmanuelle Waubant Journal: J Neurol Sci Date: 2016-02-20 Impact factor: 3.181
Authors: Despoina Manousaki; Tom Dudding; Simon Haworth; Yi-Hsiang Hsu; Ching-Ti Liu; Carolina Medina-Gómez; Trudy Voortman; Nathalie van der Velde; Håkan Melhus; Cassianne Robinson-Cohen; Diana L Cousminer; Maria Nethander; Liesbeth Vandenput; Raymond Noordam; Vincenzo Forgetta; Celia M T Greenwood; Mary L Biggs; Bruce M Psaty; Jerome I Rotter; Babette S Zemel; Jonathan A Mitchell; Bruce Taylor; Mattias Lorentzon; Magnus Karlsson; Vincent V W Jaddoe; Henning Tiemeier; Natalia Campos-Obando; Oscar H Franco; Andre G Utterlinden; Linda Broer; Natasja M van Schoor; Annelies C Ham; M Arfan Ikram; David Karasik; Renée de Mutsert; Frits R Rosendaal; Martin den Heijer; Thomas J Wang; Lars Lind; Eric S Orwoll; Dennis O Mook-Kanamori; Karl Michaëlsson; Bryan Kestenbaum; Claes Ohlsson; Dan Mellström; Lisette C P G M de Groot; Struan F A Grant; Douglas P Kiel; M Carola Zillikens; Fernando Rivadeneira; Stephen Sawcer; Nicholas J Timpson; J Brent Richards Journal: Am J Hum Genet Date: 2017-07-27 Impact factor: 11.043
Authors: Sudarshini Ramanathan; Shekeeb Mohammad; Esther Tantsis; Tina Kim Nguyen; Vera Merheb; Victor S C Fung; Owen Bruce White; Simon Broadley; Jeannette Lechner-Scott; Steve Vucic; Andrew P D Henderson; Michael Harry Barnett; Stephen W Reddel; Fabienne Brilot; Russell C Dale Journal: J Neurol Neurosurg Psychiatry Date: 2017-11-15 Impact factor: 10.154
Authors: Niklas Frahm; Melanie Peters; Jörg Bätzing; David Ellenberger; Manas K Akmatov; Judith Haas; Paulus S Rommer; Alexander Stahmann; Uwe K Zettl; Jakob Holstiege Journal: Ther Adv Neurol Disord Date: 2021-10-06 Impact factor: 6.570